## Domenico F Intiso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5537130/publications.pdf

Version: 2024-02-01

279798 1,507 60 23 citations papers

37 h-index g-index 64 64 64 2293 docs citations times ranked citing authors all docs

330143

#	Article	IF	CITATIONS
1	ICU-acquired weakness: should medical sovereignty belong to any specialist?. Critical Care, 2018, 22, 1.	5.8	145
2	Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurological Sciences, 2004, 24, 390-396.	1.9	129
3	The Rehabilitation Role in Chronic Kidney and End Stage Renal Disease. Kidney and Blood Pressure Research, 2014, 39, 180-188.	2.0	114
4	Rehabilitation of walking with electromyographic biofeedback in foot-drop after stroke Stroke, 1994, 25, 1189-1192.	2.0	82
5	Long-term functional outcome and health status of patients with critical illness polyneuromyopathy. Acta Neurologica Scandinavica, 2011, 123, 211-219.	2.1	52
6	Urgent Measures for the Containment of the Coronavirus (Covid-19) Epidemic in the Neurorehabilitation/Rehabilitation Departments in the Phase of Maximum Expansion of the Epidemic. Frontiers in Neurology, 2020, 11, 423.	2.4	52
7	Post-stroke depression: research methodology of a large multicentre observational study (DESTRO). Neurological Sciences, 2004, 25, 138-44.	1.9	44
8	Botulinum Toxin Type A for the Treatment of Neuropathic Pain in Neuro-Rehabilitation. Toxins, 2015, 7, 2454-2480.	3.4	43
9	Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. Journal of the Neurological Sciences, 2015, 350, 1-6.	0.6	42
10	Mesial temporal cortex hypoperfusion is associated with depression in subcortical stroke Stroke, 1994, 25, 980-985.	2.0	41
11	Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy. Developmental Neurorehabilitation, 2006, 9, 165-170.	1.1	38
12	Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. Drugs, 2019, 79, 143-160.	10.9	38
13	Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Developmental Medicine and Child Neurology, 2011, 53, 559-564.	2.1	37
14	Incidence of firstâ€ever ischemic and hemorrhagic stroke in a wellâ€defined community of southern Italy, 1993–1995. European Journal of Neurology, 2003, 10, 559-565.	3.3	36
15	Mobilization in early rehabilitation in intensive care unit patients with severe acquired brain injury: An observational study. Journal of Rehabilitation Medicine, 2017, 49, 715-722.	1.1	36
16	Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. Journal of Neural Transmission, 2013, 120, 469-476.	2.8	32
17	The Effect of Robotic Assisted Gait Training With Lokomat® on Balance Control After Stroke: Systematic Review and Meta-Analysis. Frontiers in Neurology, 2021, 12, 661815.	2.4	31
18	Therapeutic Use of Botulinum Toxin in Neurorehabilitation. Journal of Toxicology, 2012, 2012, 1-12.	3.0	30

#	Article	IF	CITATIONS
19	Survival and functional outcome in patients 90 years of age or older after hip fracture. Age and Ageing, 2009, 38, 619-622.	1.6	28
20	Multi-center study on overall clinical complexity of patients with prolonged disorders of consciousness of different etiologies. Brain Injury, 2021, 35, 1-7.	1.2	26
21	Occurrence of factor V Leiden mutation (Arg506Gln) and anticardiolipin antibodies in migraine patients. Neurological Sciences, 2002, 22, 455-458.	1.9	24
22	High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. NeuroRehabilitation, 2014, 34, 515-522.	1.3	24
23	Leukocyte response in patients suffering from acute stroke Stroke, 1988, 19, 1283-1284.	2.0	23
24	Brain MRI white matter lesions in migraine patients: is there a relationship with antiphospholipid antibodies and coagulation parameters?. European Journal of Neurology, 2006, 13, 1364-1369.	3.3	23
25	Prolonged Remission of Neuro-Behcet Disease following Autologous Transplantation. International Journal of Immunopathology and Pharmacology, 2007, 20, 91-96.	2.1	21
26	Effect of electrical stimulation as an adjunct to botulinum toxin type A in the treatment of adult spasticity: a systematic review. Disability and Rehabilitation, 2017, 39, 2123-2133.	1.8	21
27	Early rehabilitation for severe acquired brain injury in intensive care unit: multicenter observational study. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 90-100.	2.2	21
28	Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. Journal of the Neurological Sciences, 2017, 378, 182-186.	0.6	18
29	Identifying clinical complexity in patients affected by severe acquired brain injury in neurorehabilitation: a cross sectional survey. European Journal of Physical and Rehabilitation Medicine, 2019, 55, 191-198.	2.2	18
30	Readmission to the acute care unit and functional outcomes in patients with severe brain injury during rehabilitation. European Journal of Physical and Rehabilitation Medicine, 2017, 53, 268-276.	2.2	16
31	High Dosage of Botulinum Toxin Type A in Adult Subjects with Spasticity Following Acquired Central Nervous System Damage: Where Are We at?. Toxins, 2020, 12, 315.	3.4	16
32	Botulinum toxin type A in the healing of a chronic buttock ulcer in a patient with spastic paraplegia after spinal cord injury. Journal of Rehabilitation Medicine, 2009, 41, 1100-1102.	1.1	15
33	Rehabilitation strategy in the elderly. Journal of Nephrology, 2012, 25, 90-95.	2.0	15
34	Preoperative treatment with botulinum A toxin in patients with cervical disk herniation secondary to dystonic cerebral palsy. Neurological Sciences, 2000, 21, 63-63.	1.9	14
35	Botulinum toxin use in neuro-rehabilitation to treat obstetrical plexus palsy and sialorrhea following neurological diseases: A review. NeuroRehabilitation, 2012, 31, 117-129.	1.3	14
36	The Role of Rehabilitation in Patients With Progressive Supranuclear Palsy: A Narrative Review. PM and R, 2018, 10, 636-645.	1.6	13

#	Article	IF	CITATIONS
37	Localized muscle vibration in the treatment of motor impairment and spasticity in post-stroke patients: a systematic review. European Journal of Physical and Rehabilitation Medicine, 2021, 57, 44-60.	2.2	13
38	Recovery and long term functional outcome in people with critical illness polyneuropathy and myopathy: a scoping review. BMC Neurology, 2022, 22, 50.	1.8	12
39	Functional outcome and health status of injured patients with peripheral nerve lesions. Injury, 2010, 41, 540-543.	1.7	11
40	Functional outcome of critical illness polyneuropathy in patients affected by severe brain injury. European Journal of Physical and Rehabilitation Medicine, 2017, 53, 910-919.	2.2	11
41	Long-term outcome and health status in decompressive craniectomized patients with intractable intracranial pressure after severe brain injury. Brain Injury, 2011, 25, 379-386.	1.2	10
42	Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study. Archives of Dermatological Research, 2014, 306, 497-503.	1.9	10
43	Rehabilitation in oldest-old stroke patients: a comparison within over 65 population. European Journal of Physical and Rehabilitation Medicine, 2019, 55, 148-155.	2.2	10
44	Multi-center observational study on occurrence and related clinical factors of neurogenic heterotopic ossification in patients with disorders of consciousness. Brain Injury, 2021, 35, 530-535.	1.2	9
45	Critical Illness Polyneuropathy and Functional Outcome in Subjects with Covid-19: Report on Four Patients and a Scoping Review of the Literature. Journal of Rehabilitation Medicine, 2021, 54, jrm00257.	1.1	9
46	Bilateral periventricular nodular heterotopia associated with coeliac disease and palatoschisis. Italian Journal of Neurological Sciences, 1998, 19, 180-183.	0.1	7
47	Caregivers' engagement during inâ€hospital care of sABl's patients: Evaluation of informal coâ€production from the health providers' perspective. Health and Social Care in the Community, 2020, 28, 2086-2094.	1.6	6
48	Impact of healthcare-associated infections on functional outcome of severe acquired brain injury during inpatient rehabilitation. Scientific Reports, 2022, 12, 5245.	3.3	6
49	Botulinum toxin type A in the healing of ulcer following oro-mandibular dyskinesia in a patient in a vegetative state. Journal of Rehabilitation Medicine, 2008, 40, 315-316.	1.1	5
50	Thrombocytosis after hip and knee surgery in the rehabilitation setting: is it an occasional phenomenon? Relationship with deep venous thrombosis and functional outcome. BMC Musculoskeletal Disorders, 2015, 16, 90.	1.9	5
51	Serum vitamin D deficiency in subjects with severe acquired brain injury and relationship with functional severity. Brain Injury, 2018, 32, 1817-1823.	1.2	4
52	Healthcare-Associated Infections in Subjects With Severe Acquired Brain Injury: The Effect of Microbial Colonization on the Functional Outcome. Data From a Multicenter Observational Study. Frontiers in Neurology, 2020, 11, 563275.	2.4	3
53	User-centered practices in the eyes of informal caregivers of in-patients with severe acquired brain injury: needs, caring experience, and satisfaction. Brain Injury, 2021, , 1-11.	1.2	2
54	Ultrasonographic Evaluation of Three Approaches for Botulinum Toxin Injection into Tibialis Posterior Muscle in Chronic Stroke Patients with Equinovarus Foot: An Observational Study. Toxins, 2021, 13, 829.	3.4	2

#	Article	lF	CITATIONS
55	Post-stroke depression: a neuroimaging study. European Neuropsychopharmacology, 1992, 2, 321.	0.7	O
56	Botulinum toxin A for the treatment of ulcer caused by oro-mandibular dyskinesia in a patient with a vegetative state. Toxicon, 2008, 51, 45-46.	1.6	0
57	SP039ACUTE INTERMITTENT PORPHYRIA IN ELDERLY UNDERGOING HEMODIALYSIS: RESOLUTION OF TETRAPLEGIA WITH SYSTEMIC HEMIN AND REHABILITATION. Nephrology Dialysis Transplantation, 2017, 32, iii118-iii118.	0.7	O
58	Rehabilitation of Older Patients with Chronic Kidney Diseases. Practical Issues in Geriatrics, 2018, , $477-481$ .	0.8	0
59	Vitamin D serum level in subjects with critical illness polyneuropathy and myopathy. Journal of Musculoskeletal Neuronal Interactions, 2020, 20, 18-26.	0.1	O
60	Case Report: Functional Outcome of COVID-19 Subjects With Myasthenia Gravis and Critical Illness Polyneuropathy. Frontiers in Neurology, 0, $13$ , .	2.4	0